In the present study, we performed HTS studies using the MEK inhibitor trametinib (approved by the U.S. Food and Drug Administration for melanoma) as an anchor with two different clinically “ready” compound library sets: 1) the National Cancer Institute oncology set V and 2) a custom clinical set of compounds either approved by the U.S. Food and Drug Administration or in clinical trials. Here, MAP2K7 is linked to melanoma.